Indole Derivative Compounds for Aberrant Splicing Correction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for cancer, AIDS, and premature aging, such as Hutchinson-Gilford progeria syndrome, face challenges due to high production costs, cellular toxicity, and inefficiencies in targeting metastatic invasion and aberrant splicing events, particularly in correcting or eliminating abnormal splicing defects.
Innovation Solution
Development of specific indole derivative compounds and their derivatives, which can be administered to prevent, inhibit, or treat cancer, AIDS, and premature aging by targeting metastatic invasion and aberrant splicing events, including those related to the nuclear lamin A gene, through mechanisms that do not induce cellular toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic strategies are used to treat cancer, AIDS, and premature aging, then treatment effectiveness is achieved, but production costs are high and cellular toxicity occurs
Solution Approach 1:
The patent modifies the chemical structure of indole derivatives by changing parameters such as substituent groups (R1, R2, R3, R4, R5, R6), ring structures, and molecular configurations to develop compounds with improved therapeutic profiles. These parameter changes aim to maintain or enhance treatment effectiveness while reducing cellular toxicity and production costs compared to existing therapies
2Reliability
If current therapeutic strategies are used to treat metastatic cancer, then some treatment effect is achieved, but inefficiencies in targeting metastatic invasion occur
Solution Approach 1:
The patent designs indole derivative compounds with specific local structural features and functional groups that enable selective targeting of metastatic invasion pathways. The molecular structure is optimized to interact with specific biological targets involved in metastasis, thereby improving targeting efficiency while maintaining treatment effect
3Reliability
If current therapeutic strategies are used to correct aberrant splicing defects, then some correction is achieved, but inefficiencies in eliminating abnormal splicing events occur
Solution Approach 1:
The patent modifies indole derivative compounds to optimize their ability to correct aberrant splicing events by changing molecular parameters that affect binding affinity and specificity to splicing regulatory elements. These parameter changes aim to improve both the reliability of splicing correction and the efficiency of eliminating abnormal splicing events
Data Source
AI summary
The present disclosure is generally directed to the manufacture and use of compounds described herein for preventing, inhibiting or treating cancer, AIDS and/or premature aging, or the manufacture and use of a pharmaceutical composition comprising at least one of the compounds, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for preventing, inhibiting or treating cancer, AIDS and/or premature aging.